Titlebook: Homocysteine and Vascular Disease; Killian Robinson Book 2000 Springer Science+Business Media Dordrecht 2000 cardiovascular.coronary arter

Noisome

Reference Ranges for Homocysteine Concentrations,nd who may have sub-clinical disease. Furthermore, the validity of the plasma homocysteine reference range may be affected by certain confounding variables, e.g. use of different analytical methods and standards, gender, age, vitamin nutritional status, and race. In this chapter the plasma homocyste

純樸

engrossed

Vascular Pathology of Hyperhomocysteinemia,hydrofolate reductase deficiency, confirmed the association between arteriosclerosis and hyperhomocysteinemia, regardless of which particular inherited enzyme abnormality causes the elevation of blood homocysteine levels. The vascular pathology associated with moderate hyperhomocysteinemia in subjec

話

Vascular Complications of Homocystinuria: Incidence, Clinical Pattern and Treatment,ture death. Homocystinuric patients show considerable heterogeneity in their clinical picture. In homocystinuria, thrombophiebitis and pulmonary embolism are the most frequent vascular events, although pulmonary embolism is seldom a cause of death. Thrombosis of large and medium size-arteries such a

轉折點

Homocysteine as a Risk Factor for Peripheral Vascular Disease,studies excluding patients with standard risk factors (diabetes mellitus, hypertension, elevated lipids) or statistically eliminating these factors, elevated homocysteine has been shown to be an independent risk factor for the presence of peripheral vascular disease. Moreover, the magnitude of the r

SMART

Homocysteine as a Risk Factor for Cerebrovascular Disease and Stroke,ther vascular disease. There is a need for additional prospective studies with sufficient power to characterise the form of the association between homocysteine concentrations and cerebrovascular disease risk, whether linear or threshold, and to study the independent effects of homocysteine concentr

Irremediable

Homocysteine as a Risk Factor for Coronary Artery Disease,CHD risk factors also is indicated, particularly among patients known to have atherosclerotic vascular disease. Verification of the clinical benefit and safety of homocysteine-lowering will require the completion during the next 5 to 10 years of 10 ongoing large scale prospective randomized clinical

Terminal

Homocysteine as a Risk Factor for Cardiovascular Disease in Women, that consisted (almost) entirely of women observed a direct association of elevated homocysteine with CVD risk as well, comparable to effects in male populations..The stronger effect among women in some studies may be explained by aspects of the study design, such as young age at inclusion, or aspe

ANTIC

Homocysteine and Venous Thrombosis,plied to venous thrombosis as well. However, up to now there is no satisfying model which might explain a thrombophilic state at concentrations in the range of mild hyperhomocysteinemia.The clinical relevance of the finding that hyperhomocysteinemia is a risk factor for venous thrombosis depends mai

geriatrician